Undesirable effects of citrus juice on the pharmacokinetics of drugs - Focus on recent studies

被引:69
作者
Saito, M [1 ]
Hirata-Koizumi, M [1 ]
Matsumoto, M [1 ]
Urano, T [1 ]
Hasegawa, R [1 ]
机构
[1] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan
关键词
D O I
10.2165/00002018-200528080-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
It is well known that intake of grapefruit juice affects the pharmacokinetics of various kinds of drugs. It has been reported that other citrus juices also interact with certain drugs. To re-evaluate citrus juice-drug interactions based on currently available evidence, a literature search was conducted for new and updated information since the grapefruit juice-drug interaction was last reviewed in 1998. MEDLINE (1998-October 2004) was accessed and more than 200 reports were found. The effects of grapefruit juice ingestion on the pharmacokinetics of orally administered drugs have been reported for 40 drugs since the reviews published in 1998. Increases in either area under the concentration-time curve (AUC) or maximum plasma concentration (C-max) were found with 34 of these, the major mechanism being considered to be inactivation of intestinal cytochrome P450 3A4, a so-called mechanism-based inhibition. Although recent reports point to the inhibitory effects of grapefruit juice on the function of P-glycoprotein, which transports substrates from enterocytes back into the lumen, the contribution to the bioavailability of drugs that are substrates of P-glycoprotein has not been established yet. Dramatic decreases in AUC and C-max for two drugs in association with grapefruit juice ingestion has been reported and, in these cases, inhibitory effects on organic anion transporting polypeptide, which mediates absorption from the intestinal lumen to enterocytes, might be involved. Other citrus juices such as Seville (sour) orange juice and commonly ingested varieties of orange juice also showed significant effects on the AUC and C-max of some drugs. Although the situation is complex and uncertainties remain, we recommend that patients avoid citrus juice intake while taking medications and that healthcare providers advise against citrus juice intake in this setting until any interactions with subject drugs can be clarified in clinical studies.
引用
收藏
页码:677 / 694
页数:18
相关论文
共 124 条
[1]   Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation [J].
Backman, JT ;
Mäenpää, J ;
Belle, DJ ;
Wrighton, SA ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (04) :382-390
[2]   Interactions between grapefruit juice and cardiovascular drugs [J].
Bailey D.G. ;
Dresser G.K. .
American Journal of Cardiovascular Drugs, 2004, 4 (5) :281-297
[3]   Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: Comparison with grapefruit juice [J].
Bailey, DG ;
Dresser, GK ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :529-537
[4]   GRAPEFRUIT JUICE AND DRUGS - HOW SIGNIFICANT IS THE INTERACTION [J].
BAILEY, DG ;
ARNOLD, JMO ;
SPENCE, JD .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :91-98
[5]  
Bailey DG, 2004, NUTR HLTH, P175
[6]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[7]   EFFECT OF GRAPEFRUIT JUICE AND NARINGIN ON NISOLDIPINE PHARMACOKINETICS [J].
BAILEY, DG ;
ARNOLD, JMO ;
STRONG, HA ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :589-594
[8]   Grapefruit juice felodipine interaction:: Effect of naringin and 6′,7′-dihydroxybergamottin in humans [J].
Bailey, DG ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :248-256
[9]   INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE [J].
BAILEY, DG ;
SPENCE, JD ;
MUNOZ, C ;
ARNOLD, JMO .
LANCET, 1991, 337 (8736) :268-269
[10]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110